Background: Brain cancer diagnoses are rare and associated with poor prognoses. Medical imaging is crucial for personalised oncological care. Few studies have examined factors for recruitment and retention in CNS imaging-based non-intervention trials.
Aims: We explored perspectives of glioblastoma patients, carers, and healthcare professionals (HCP) regarding participation in the “Prospective, multicentre trial evaluating FET-PET in Glioblastoma (ACTRN12619001735145)” (FIG) trial, which is evaluating whether a new approach to imaging (FET-PET scans) leads to more accurate assessment and management of people with glioblastoma. Here we report perspectives from patients and carers.
Methods: Individuals who met eligibility for the FIG trial, both participants and those who declined, were eligible along with a nominated carer. Between November 2024 and March 2026, qualitative interviews were undertaken separately with patients and carers from four FIG trial sites. Semi-structured telephone interviews were audio-recorded and transcribed. A subset of patient transcripts were randomly selected and inductively analysed by two research team members to identify preliminary themes and generate an initial framework. The framework was deductively applied to all remaining transcripts.
Results: Seventeen people with glioblastoma and 14 carers were interviewed. Most spoke English (n=29/31, 94%) and took part in FIG (n=26/31, 84%). Seven themes were identified: (1) Perceived risks and benefits of imaging research and impact of competing intervention trials; (2) Perceived ease of and familiarity with scans; (3) Altruistic motivations (“change for future patients” and “supporting brain cancer research”); (4) Timing of research participation discussions; (5) Trust in/influence of clinicians in research decision-making; (6) Logistical and administrative factors; and, (7) Role of carer in decision-making and support.
Conclusions: We identified factors influencing recruitment and retention in non-interventional brain cancer clinical trials. Our study can inform development of decision-support tools and patient-centred approaches, supporting patients in navigating participation and addressing barriers in cancer imaging studies.